Drug Trial Radar · NCT07750873
A Trial of CRD-4730 in HFrEF
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
525
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
Sep 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CRD-4730 is a calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor. The CALIBRATE-HF trial is a Phase 2, global, multi-center, randomized, double-blind, parallel-group, placebo-controlled trial. The trial will evaluate the efficacy, safety, and tolerability of CRD-4730 in addition to guideline directed medical therapy in participants with heart failure with reduced ejection fraction (HFrEF). Participants will be randomized to 1 of 4 study groups and receive investigational study drug or placebo twice daily (BID) for 24 weeks of treatment.
Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
CRD-4730Drug
Experimental, Dose A, B and C
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Composite Z-Score at 24 weeksTime frame: Baseline and Week 24
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Cardurion Investigative Site
Pasadena, California · Recruiting
Cardurion Investigative Site
Bloomfield Hills, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.